Skip to main content
SpringerLink
Log in

Psychoses

  • Chapter
The Practitioner’s Guide to Psychoactive Drugs

Abstract

The focus of this chapter is on antipsychotic agents—drugs also known as neuroleptics, antischizophrenic agents, and major tranquilizers (a misnomer). This pharmacological family has become a mainstay in the treatment of schizophrenia and other psychotic disorders as well as many nonpsychotic conditions . We deal primarily with the phenothiazines and related antipsychotic drugs but briefly discuss various experimental agents. The chapter also describes other approaches to treating psychoses and concludes by discussing future directions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. May P. R. A., Tuma A. H., Yale C., et al: Schizophrenia-a follow-up study of results of treatment. II. Hospital stay over two to five years. Arch Gen Psychiatry 33:431–506, 1976.

    Article  Google Scholar 

  2. Hogarty G. E., Goldberg S. C., Schooler N. R., et al: Drugs and social therapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 31:603–608, 1974.

    Article  PubMed  CAS  Google Scholar 

  3. Epstein N. B., Vlok L. A.: Research on the results of psychotherapy: A summary of evidence. Am J Psychiatry 138:1027–1035, 1981.

    PubMed  CAS  Google Scholar 

  4. Schooler N.R.: The efficacy of antipsychotic drugs and family therapies in the maintenance treatment of schizophrenia. J Clin Psychopharmacol 6:11S-19S, 1986.

    Article  Google Scholar 

  5. Gelenberg A. J.: The catatonic syndrome. Lancet 1:1339–1341, 1976.

    Article  PubMed  CAS  Google Scholar 

  6. Gelenberg A. J.: ECT: Controversies and consensus. Mass Gen Hosp Newslett Biol Ther Psychiatry 8:29–32, 1985.

    Google Scholar 

  7. Bartlett J., Bridges P., Kelly D.: Contemporary indications for psychosurgery. Br J Psychiatry 138:507–511, 1981.

    Article  PubMed  CAS  Google Scholar 

  8. Lipton M. A., Mailman R. B., Nemeroff C. B.: Vitamins, megavitamin therapy, and the nervous system, in Wurtman R. J., Wurtman J. J. (eds): Nutrition and the Brain, vol 3: Disorders of Eating and Nutrients in Treatment of Brain Diseases. New York, Raven Press, 1979, pp 183–264.

    Google Scholar 

  9. Gelenberg A. J.: Psychiatric disorders. In: Paige, D. M. (ed): Clinical Nutrition, ed 2. St. Louis: C V Mosby, 1988, pp 419–420.

    Google Scholar 

  10. Bassuk E. L.: The homelessness problem. Sci Am 251:40–45, 1984.

    Article  PubMed  CAS  Google Scholar 

  11. McEvoy J. P.: The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 27:327–335, 1986.

    Article  PubMed  CAS  Google Scholar 

  12. McEvoy J. P., Stiller R. L., Farr R.: Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 6:133–138, 1986.

    Article  PubMed  CAS  Google Scholar 

  13. Chouinard G., Jones B. D.: Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137:16–31, 1980.

    PubMed  CAS  Google Scholar 

  14. Ross C. A.: Buspirone in the treatment of tardive dyskinesia. Med Hypoth 22:321–328, 1987.

    Article  CAS  Google Scholar 

  15. Cohen B. M., Lipinski J. F.: In vivo potencies of antipsychotic drugs in blocking alpha-1 noradrenergic and dopamine D-2 receptors: Implications for drug mechanisms of action. Life Sci 39:2571–2580, 1987.

    Article  Google Scholar 

  16. Gelenberg A. J.: Treating the outpatient schizophrenic. Postgrad Med 64:48–56, 1978.

    PubMed  CAS  Google Scholar 

  17. Taylor W. J., Caviness M. H. D.: A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Irving, Texas, Abbott Laboratories, 1986, p. 467.

    Google Scholar 

  18. Ko G. N., Korpi E. R., Linnoila M.: On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 5:253–262, 1985.

    Article  PubMed  CAS  Google Scholar 

  19. Keepers G. A., Clappison V. J., Casey D. E.: Initial anticholinergic prophylaxis for neurolepticinduced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117, 1983.

    Article  PubMed  CAS  Google Scholar 

  20. VanPutten T., Mutalipassi L. R., Malkin M. O.: Phenothiazine-induced decompensation. Arch Gen Psychiatry 30:102–106, 1974.

    Article  PubMed  Google Scholar 

  21. Gelenberg A. J., Mandel M. R.: Catatonic reactions to high potency neuroleptic drugs. Arch Gen Psychiatry 34:947–950, 1977.

    Article  PubMed  CAS  Google Scholar 

  22. Rifkin A., Quitkin F., Klein D. F.: Akinesia: A poorly recognized drug-induced extrapyramidal behavior disorder. Arch Gen Psychiatry 32:642–674, 1975.

    Article  Google Scholar 

  23. Wojcick J. D.: Antiparkinson drug use. Mass Gen Hosp Biol Ther Psychiatry Newslett 2:5–7, 1979.

    Google Scholar 

  24. Gelenberg A. J., VanPutten T., Lavori P., et al: Anticholinergic effects on memory: Benztropine versus amantadine. J Clin Psychopharmacol 9:180–185, 1989.

    Article  PubMed  CAS  Google Scholar 

  25. Gelenberg A. J.: Amantadine in the treatment of benztropine-refractory neuroleptic-induced movement disorders. Curr Ther Res 23:375–380, 1978.

    Google Scholar 

  26. Smith J. M.: Abuse of the antiparkinson drugs: A review of the literature. J Clin Psychiatry 41:351–354, 1980.

    PubMed  CAS  Google Scholar 

  27. Jeste D. V., Wyatt R. J.: Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 138:297–309, 1981.

    Article  PubMed  CAS  Google Scholar 

  28. Burke R. E., Fahn S., Jankovic J., et al: Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32:1335–1346, 1982.

    Article  PubMed  CAS  Google Scholar 

  29. Morgenstern H., Glazer W. H., Niedzwiecki D., et al: The impact of neuroleptic medication on tardive dyskinesia: A meta-analysis of published studies. Am J Public Health 77:717–724, 1987.

    Article  PubMed  CAS  Google Scholar 

  30. Wojcik J. D., Gelenberg A. J., Labrie R. A., et al: Prevalence of tardive dyskinesia in an outpatient population. Comp Psychiatry 21:370–380, 1980.

    Article  CAS  Google Scholar 

  31. Kane J. M., Woerner M., Borenstein M., et al: Integrating incidence and prevalence of tardive dyskinesia. Read before the IVth World Congress of Biological Psychiatry, Philadelphia, Sept 8–13, 1985.

    Google Scholar 

  32. Yassa R., Nair V., Dimitry R.: Prevalence of tardive dyskinesia. Acta Psychiatr Scand 73:629–633, 1986.

    Article  PubMed  CAS  Google Scholar 

  33. Gardos G., Cole J. O., Tarsy D.: Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 135:1321–1324, 1978.

    PubMed  CAS  Google Scholar 

  34. Quitkin F., Rifkin A., Gochfeld L., et al: Tardive dyskinesia: Are first signs reversible? Am J Psychiatry 134:84–87, 1977.

    PubMed  CAS  Google Scholar 

  35. Baldessarini R. J., Tarsy D.: Tardive dyskinesia, in Lipton M. A., DiMascio A., Killam K. F. (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 993–1004.

    Google Scholar 

  36. Casey D. E., Povisen U. J., Meidahl B., et al: Neuroleptic-induced tardive dyskinesia and parkinsonism: Changes during several years of continuing treatment. Psychopharmacol Bull 8(22):250–253, 1986.

    Google Scholar 

  37. Yagi G., Itoh H.: A ten-year follow-up study of tardive dyskinesia—with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med 34:211–219, 1985.

    Article  PubMed  CAS  Google Scholar 

  38. Gelenberg A. J., Dorer D., Wojcik J., et al: A crossover study of lecithin for tardive dyskinesia. J Clin Psychiatry 51:149–153, 1990.

    PubMed  CAS  Google Scholar 

  39. Caroff S. N.: The neuroleptic malignant syndrome. J Clin Psychiatry 41:79–83, 1980.

    PubMed  CAS  Google Scholar 

  40. Gelenberg A. J., Bellinghausen B., Wojcik J. D., et al: A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 145:517–518, 1988.

    PubMed  CAS  Google Scholar 

  41. Shalev A., Munitz H.: The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatrica Scand 73:337–347, 1986.

    Article  CAS  Google Scholar 

  42. Levinson D. F., Simpson G. M.: Neuroleptic-induced extrapyramidal symptoms with fever: Heterogeneity of the “neuroleptic malignant syndrome.” Arch Gen Psychiatry 43:839–848, 1986.

    Article  PubMed  CAS  Google Scholar 

  43. Gelenberg A. J., Bellinghausen B., Wojcik J. D., et al: Patients with NMS histories: What happens when they are rehospitalized? J Clin Psychiatry 50:178–180, 1989.

    PubMed  CAS  Google Scholar 

  44. Baldessarini R. J., Gelenberg A. J.: Using physostigmine safely. Am J Psychiatry 136:1608–1609, 1979.

    PubMed  CAS  Google Scholar 

  45. Lieberman J. A., Johns C. A., Kane J. M., Rai K., Pisciotta A. V., Saltz B. L., Howard A.: Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 49:271–277, 1988.

    PubMed  CAS  Google Scholar 

  46. Zarrabi M. H., Zucker S., Miller F., et al: Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 91:194–199, 1979.

    PubMed  CAS  Google Scholar 

  47. Zucker S., Zarrabi H. M., Schuback W. H., et al. : Chlorpromazine-induced immunopathy: Progressive increase in serum IgM. Medicine 69:92–100, 1990.

    PubMed  CAS  Google Scholar 

  48. Gelenberg A. J.: Psychotropic drugs during pregnancy and the perinatal period. Mass Gen Hosp Biol Ther Psychiatry Newslett 2:41–42, 1979.

    Google Scholar 

  49. Chouinard G., Jones B. D.: Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137:16–21, 1980.

    PubMed  CAS  Google Scholar 

  50. Rivera-Calimlim L., Castaneda L., Lasagna L. : Effect of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 14:978–986, 1973.

    PubMed  CAS  Google Scholar 

  51. Dysken M. W., Javaid J. I., Chang S. S., et al: Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73:205–210, 1981.

    Article  PubMed  CAS  Google Scholar 

  52. Cohen W. J., Cohen N. H.: Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 230:1283–1287, 1974.

    Article  PubMed  CAS  Google Scholar 

  53. Spring G. K.: Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 40:135–138, 1979.

    PubMed  CAS  Google Scholar 

  54. Gelenberg A. J.: Is it safe to co-prescribe lithium with a neuroleptic? Mass Gen Hosp Biol Ther Psychiatry Newslett 2:13, 1979.

    Google Scholar 

  55. Rivera-Calimlim L., Kerzner B., Karch F. E.: Effect of lithium on plasma chlorpromazine level. Clin Pharmacol Ther 23:451–455, 1978.

    PubMed  CAS  Google Scholar 

  56. Gelenberg A. J.: Coffee, tea, and antipsychotic drugs revisited. Mass Gen Hosp Biol Ther Psychiatry Newslett 4:42–43, 1981.

    Google Scholar 

  57. Gelenberg A. J.: Psychiatric emergencies: The psychotic patient. Drug Ther May 1981 pp 25–36.

    Google Scholar 

  58. Granacher R. P. Jr: Management of the acutely psychotic patient. Read before the Symposium on Antipsychotic Drug Therapy: Current Concepts and Future Trends, Key Biscayne, Florida, March 28, 1986.

    Google Scholar 

  59. Marner S. R., Putten T., Mintz J., et al: Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 44:518–521, 1987.

    Article  Google Scholar 

  60. Kane J., Honigfeld G., Singer J., Meltzer H.: The Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison vs chlorpromazine/ benztropine. Arch Gen Psychiatry 45:789–796, 1988.

    Article  PubMed  CAS  Google Scholar 

  61. Meltzer H. Y.: Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Letter to editor. Arch Gen Psychiatry 46:672, 1989.

    Article  PubMed  CAS  Google Scholar 

  62. Lieberman J. A., Kane J. M., Johns C. A.: Clozapine: Guidelines for clinical management, J Clin Psychiatry 50:329–338, 1989.

    PubMed  CAS  Google Scholar 

  63. Lader M.: Introduction to Psychopharmacology. Kalamazoo, Upjohn, 1980, p 30.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Arizona Health Sciences Center, Tucson, Arizona, 85724, USA

    Alan J. Gelenberg M.D.

Authors
  1. Alan J. Gelenberg M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Arizona Health Sciences Center, Tucson, Arizona, USA

    Alan J. Gelenberg M.D.

  2. The Better Homes Foundation, Newton Centre, Massachusetts, USA

    Ellen L. Bassuk M.D.

  3. Harvard Medical School, Boston, Massachusetts, USA

    Ellen L. Bassuk M.D.

  4. Schoonover Associates, Newton Centre, Massachusetts, USA

    Stephen C. Schoonover M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gelenberg, A.J. (1991). Psychoses. In: Gelenberg, A.J., Bassuk, E.L., Schoonover, S.C. (eds) The Practitioner’s Guide to Psychoactive Drugs. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1137-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-1137-0_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-1139-4

  • Online ISBN: 978-1-4757-1137-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation